Skip to content

Pilot Study for Automated Deep Brain Stimulation Programming

DBS-Expert: Automated Deep Brain Stimulation Programming Using Functional Mapping - Phase I

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02046863
Enrollment
7
Registered
2014-01-28
Start date
2013-11-30
Completion date
2014-08-31
Last updated
2016-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bradykinesia, Parkinson's Disease, Tremor

Keywords

Parkinson's disease, Tremor, Bradykinesia, Deep brain stimulation, Kinesia

Brief summary

The clinical utility of deep brain stimulation (DBS) for the treatment of movement disorders such as Parkinson's disease has been well established; however, there is a great disparity in outcomes among DBS recipients due to varied postoperative management, particularly concerning the choosing of an optimal set of programming parameters from the thousands of possible combinations. This study will evaluate the use of motion sensor based assessments to develop a functional map and algorithms to automatically determine a set of programming parameters that maximize symptomatic benefits while minimizing side effects and battery consumption.

Interventions

DEVICEAutomated Programming

Prototype DBS-Expert software will be used to guide a clinician through DBS programming.

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
University of Cincinnati
CollaboratorOTHER
Great Lakes NeuroTechnologies Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of idiopathic Parkinson's disease * Implanted deep brain stimulation system awaiting initial programming session

Exclusion criteria

* Subjects with significant psychiatric illness or dementia * Significant cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Percent Change From Baseline in Kinesia HomeView Symptom Ratings After Guided DBS ProgrammingWithin two days of standard clinical DBS programming sessionSymptoms were first assessed with the implanted pulse generator (IPG) turned off for at least 30 minutes to allow the after-effects of stimulation to wear off (baseline). Symptoms were measured again with the IPG turned on at a setting that both minimized the average severity of tremor and bradykinesia and minimized side effects. The Kinesia score rated symptom severity (0, normal; 4, most severe) in four categories: tremor, finger tapping speed, finger tapping amplitude, and finger tapping rhythm. Scores for the four motor symptoms were averaged and converted to percent change from baseline.

Countries

United States

Participant flow

Participants by arm

ArmCount
Automated Programming
Subjects will have DBS settings changed as guided by prototype DBS-Expert software. Tremor, bradykinesia, and dyskinesia will be assessed at each DBS setting. Automated Programming: Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
7
Total7

Baseline characteristics

CharacteristicAutomated Programming
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
1 Participants
Age, Categorical
Between 18 and 65 years
6 Participants
Age, Continuous62 years
Region of Enrollment
United States
7 participants
Sex: Female, Male
Female
2 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 7
serious
Total, serious adverse events
0 / 7

Outcome results

Primary

Percent Change From Baseline in Kinesia HomeView Symptom Ratings After Guided DBS Programming

Symptoms were first assessed with the implanted pulse generator (IPG) turned off for at least 30 minutes to allow the after-effects of stimulation to wear off (baseline). Symptoms were measured again with the IPG turned on at a setting that both minimized the average severity of tremor and bradykinesia and minimized side effects. The Kinesia score rated symptom severity (0, normal; 4, most severe) in four categories: tremor, finger tapping speed, finger tapping amplitude, and finger tapping rhythm. Scores for the four motor symptoms were averaged and converted to percent change from baseline.

Time frame: Within two days of standard clinical DBS programming session

ArmMeasureValue (MEAN)Dispersion
Automated ProgrammingPercent Change From Baseline in Kinesia HomeView Symptom Ratings After Guided DBS Programming-35.7 Percentage changeStandard Deviation 37.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026